Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,485 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,566 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03742297 | Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years | active not recruiting | Phase 3 | 462 | PETHEMA FoundationOTHER | 1 | Sep 14, 2022 | clinicaltrials |
| NCT02415413 | Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma | active not recruiting | Phase 2 | 90 | PETHEMA FoundationOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT04361162 | Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer | active not recruiting | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05190445 | Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma | active not recruiting | Phase 2 | 80 | Pieris Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 8, 2022 | clinicaltrials |
| NCT03645824 | Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)(HOVON134MF) | active not recruiting | Phase 2 | 61 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 2 | Aug 22, 2022 | clinicaltrials |
| NCT04214886 | CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies | active not recruiting | Phase 1 | 24 | Loyola UniversityOTHER | 1 | Aug 15, 2022 | clinicaltrials |
| NCT04486911 | Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial | active not recruiting | Phase 2 | 89 | Shengjing HospitalOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05459415 | Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced HNSCC | active not recruiting | N/A | 54 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT01744223 | Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 36 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT02477878 | Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | active not recruiting | Phase 1 | 10 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT03301168 | Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 120 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT03459170 | Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant | active not recruiting | Phase 1 | 15 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT01464216 | MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness(FuncProst) | active not recruiting | — | 120 | Oslo University HospitalOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT02623933 | MRI Assisted Focal Boost With HDR Monotherapy for Prostate Cancer Patients(MARS) | active not recruiting | N/A | 60 | Sunnybrook Health Sciences CentreOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT04024475 | Prostate Cancer Biobank | active not recruiting | — | 1,323 | Swiss Cancer InstituteOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT03585114 | Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers | active not recruiting | Phase 2 | 11 | Columbia UniversityOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT03824275 | 18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer | active not recruiting | Phase 2 / Phase 3 | 129 | Columbia UniversityOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT03444844 | Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 60 | Five Eleven Pharma, Inc.INDUSTRY | 1 | May 2, 2022 | clinicaltrials |
| NCT02938702 | Active Surveillance on Papillary Thyroid Microcarcinoma | active not recruiting | — | 1,211 | Seoul National University HospitalOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT03836352 | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | active not recruiting | Phase 2 | 184 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Mar 31, 2022 | clinicaltrials |
| NCT02243033 | Phase II Laser Focal Therapy of Prostate Cancer(LITT or FLA) | active not recruiting | — | 1,000 | HALO DiagnosticsINDUSTRY | 1 | Mar 25, 2022 | clinicaltrials |
| NCT03993665 | Use of Multiparametric MRI in the Management of Head and Neck Cancer: a Prospective Analysis | active not recruiting | — | 70 | AZ Sint-Jan AVOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT02339779 | Breast Reconstruction With External Pre-expansion and Autologous Fat Transfer Versus Standard Therapy(BREAST) | active not recruiting | N/A | 196 | Maastricht University Medical CenterOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT03308396 | Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | Ajjai Alva, MDOTHER | 1 | Feb 17, 2022 | clinicaltrials |
| NCT03179943 | Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma | active not recruiting | Phase 2 | 21 | Fox Chase Cancer CenterOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT02603679 | Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases(PREDIX LumB) | active not recruiting | Phase 2 | 181 | Thomas HatschekOTHER | 1 | Aug 3, 2021 | clinicaltrials |
| NCT02113384 | Locally Advanced Rectal Cancer - Exfoliated Peritoneal Tumor Cells(LARC-EX) | active not recruiting | — | 231 | Oslo University HospitalOTHER | 1 | Jul 28, 2021 | clinicaltrials |
| NCT03709719 | Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia(GRAALL-QUEST) | active not recruiting | Phase 2 | 95 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT03606577 | An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients(IFM 2018-04) | active not recruiting | Phase 2 | 50 | Nantes University HospitalOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04848545 | Endocrine Disrupting Chemical Exposure and Testicular Cancer(DISRUPT) | active not recruiting | — | 700 | Rigshospitalet, DenmarkOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT03820778 | Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 | active not recruiting | N/A | 10 | Children's National Research InstituteOTHER | 1 | Mar 2, 2021 | clinicaltrials |
| NCT02319928 | European Polyp Surveillance Trial(EPoS) | active not recruiting | N/A | 20,000 | Asociación Española de GastroenterologíaOTHER | 1 | Jan 12, 2021 | clinicaltrials |
| NCT02775227 | HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications(HYPAR) | active not recruiting | Phase 4 | 126 | Helsinki University Central HospitalOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT02568839 | Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer(PREDIX HER2) | active not recruiting | Phase 2 / Phase 3 | 202 | Thomas HatschekOTHER | 1 | Aug 13, 2020 | clinicaltrials |
| NCT03669965 | KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera | active not recruiting | Phase 2 | 20 | Kartos Therapeutics, Inc.INDUSTRY | 6 | Jul 31, 2020 | clinicaltrials |
| NCT03284593 | Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition(LAM-BDD) | active not recruiting | — | 199 | University Hospital, ToulouseOTHER | 1 | Jul 30, 2020 | clinicaltrials |
| NCT02592083 | Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors(PREDIX LumA) | active not recruiting | Phase 2 | 10 | Thomas HatschekOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT02447549 | Study of Tumour Focused Radiotherapy for Bladder Cancer(RAIDER) | active not recruiting | Phase 2 | 345 | Institute of Cancer Research, United KingdomOTHER | 3 | Jun 9, 2020 | clinicaltrials |
| NCT02338310 | Trial of Perioperative Endocrine Therapy - Individualising Care(POETIC) | active not recruiting | Phase 3 | 4,486 | Institute of Cancer Research, United KingdomOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01688908 | Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC)(ESECC) | active not recruiting | N/A | 33,948 | Peking UniversityOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT03391843 | Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer | active not recruiting | Phase 2 | 100 | RenJi HospitalOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT02482454 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma | active not recruiting | Phase 2 / Phase 3 | 50 | The First People's Hospital of ChangzhouOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT00883792 | The Northern-European Initiative on Colorectal Cancer(NordICC) | active not recruiting | Phase 3 | 95,000 | Oslo University HospitalOTHER | 6 | Jun 19, 2017 | clinicaltrials |
| NCT03047265 | Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 164 | Sun Yat-sen UniversityOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT02487992 | The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer | active not recruiting | Phase 2 | 1,200 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 24, 2016 | clinicaltrials |
| NCT02487693 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma | active not recruiting | Phase 2 | 50 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 23, 2016 | clinicaltrials |
| NCT02490748 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer | active not recruiting | Phase 2 | 10 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 23, 2016 | clinicaltrials |
| NCT02491697 | Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer | active not recruiting | Phase 2 | 400 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 23, 2016 | clinicaltrials |
| NCT02489890 | CIK in Treating Patients With Bladder Cancer | active not recruiting | Phase 2 | 1,500 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 22, 2016 | clinicaltrials |
| NCT02496273 | Phase I Trial of CEA Specific AAV-DC-CTL Treatment in Stage IV Gastric Cancer | active not recruiting | Phase 1 | 60 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 22, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Sep 14, 2022source: clinicaltrials